Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Phase I clinical trial of novel cervical dysplasia Rx from StressGen

Feb. 3, 1999

SWOG phase II study of safety and efficacy of rhIL-4 in malignant melanoma

Jan. 25, 1999

Polish authorities allow phase II testing of Multikine

Jan. 15, 1999

Health Canada approves new indication for Proleukin

Jan. 12, 1999

Proleukin receives orphan drug status for two new indications

Jan. 7, 1999

Anticancer immunotoxin available for licensing from NIH

Jan. 4, 1999

Promising phase III trial results presented for Coulter's lead cancer therapy

Dec. 29, 1998

Merck obtains option to expand MDX-447 collaboration with Medarex

Dec. 29, 1998

FDA grants fast track designation for OvaRex MAb

Dec. 22, 1998

Cell Genesys and Japan Tobacco enter worldwide collaboration for GVAX cancer vaccine

Dec. 22, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Viva in vivo! At EHA, in vivo CAR T data continues to impress
BioWorld
Treatment with first-generation CAR T cells regularly sent patients to the intensive care unit. Now, investigators are envisioning a future where CAR T treatment...